Financial Performance - The company's revenue for Q1 2025 was ¥2,435,873,177.34, representing a 9.17% increase compared to ¥2,231,209,294.86 in the same period last year[5] - Net profit attributable to shareholders decreased by 5.26% to ¥624,758,641.94 from ¥659,412,768.43 year-on-year[5] - The net cash flow from operating activities was ¥657,714,515.09, down 2.64% from ¥675,553,263.28 in the previous year[5] - Total operating revenue for the current period reached ¥2,435,873,177.34, an increase of 9.2% compared to ¥2,231,209,294.86 in the previous period[30] - Net profit for the current period was ¥623,182,616.76, a decrease of 5.7% from ¥661,025,126.81 in the previous period[32] - Basic and diluted earnings per share were both ¥0.6271, down from ¥0.6619 in the prior period[32] - The company reported a total profit of ¥737,099,415.22, down from ¥778,193,564.96 in the previous period, reflecting a decline in overall profitability[32] Assets and Liabilities - Total assets increased by 4.93% to ¥16,416,376,751.82 from ¥15,645,782,499.04 at the end of the previous year[5] - The company's total liabilities as of March 31, 2025, were CNY 3,189,273,124.05, with current liabilities totaling CNY 2,900,863,483.46[28] - The company's total equity as of March 31, 2025, was CNY 13,227,103,627.77, reflecting a strong financial position[28] - Cash and cash equivalents increased to CNY 7,079,594,847.56 from CNY 6,618,648,637.69, indicating improved liquidity[26] Cash Flow - The net cash flow from investing activities decreased by 589.34%, mainly due to strategic investments in directed share placements[9] - The company experienced a 97.64% increase in net cash flow from financing activities, primarily due to last year's loan repayments[9] - Cash flow from operating activities generated a net amount of ¥657,714,515.09, slightly down from ¥675,553,263.28 in the previous period[34] - The company received cash inflows from operating activities totaling ¥2,358,650,181.12, an increase from ¥2,281,354,434.16 in the previous period[34] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 49,184[11] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of shares, totaling 245,983,450 shares[11] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 24.54%[11] - As of February 26, 2025, the employee stock ownership plan holds 6,010,616 shares, accounting for 0.60% of the company's total share capital[21] Investments and Partnerships - The company has invested up to RMB 60 million in the Nanjing Shengyu Heike New Intelligent Manufacturing Venture Capital Partnership[14] - The company subscribed to 2,626,425 shares of Inogen, representing 9.9% of Inogen's issued common stock after the investment[16] - The company has established a strategic cooperation agreement with Inogen for international distribution, trademark licensing, joint R&D, and supply chain optimization[16] - The company has completed the capital contribution to the partnership and will not need to make further contributions[14] Product Development and Innovation - The company received a medical device registration certificate for its 15-day calibration-free/calibrated dual-mode continuous glucose monitoring system[18] - The company aims to enhance product offerings in diabetes care solutions, focusing on accuracy, comfort, convenience, and digital management[18] - The company received the medical device registration certificate for the Continuous Glucose Monitoring System (CGM), which has a maximum usage time of 16 days and does not require user calibration, enhancing user experience and expanding the product matrix in blood glucose management[19] - The company’s automatic external defibrillator (AED) has obtained EU MDR certification, enhancing its competitiveness in the emergency medical field and facilitating business development in EU countries[23] - Research and development expenses increased to ¥156,329,663.86, up 25.6% from ¥124,450,232.82 in the prior period, indicating a focus on innovation[31] Operational Costs - Total operating costs amounted to ¥1,816,105,564.51, up 14.6% from ¥1,584,225,003.71 in the prior period, with operating costs specifically rising to ¥1,210,554,322.86, a 8.4% increase from ¥1,116,936,863.37[31] - Sales expenses rose by 32.67%, primarily due to increases in salaries, bonuses, and advertising costs[8] Other Financial Information - Other comprehensive income after tax showed a net loss of ¥53,795,499.78, compared to a loss of ¥2,952,891.55 in the previous period[32] - The first quarter report has not been audited[36] - The new accounting standards will be implemented starting in 2025[36] - The financial statement items related to the first year of implementation will be adjusted accordingly[36] - The board of directors of Jiangsu Yuyue Medical Equipment Co., Ltd. issued the report on April 26, 2025[36]

江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2024年三季报，公司实现营业收入60.28亿元，同比-9.53%；净利润15.32亿元，同 比-30.09%，销售毛利率50.13%。 4月25日，鱼跃医疗今日收盘33.21元，下跌3.26%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到19.17倍，总市值332.92亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)44鱼跃医疗19.1713.902.66332.92亿行业平均 45.1147.464.59101.63亿行业中值33.8331.852.2945.98亿1 ...

Group 1 - The core viewpoint of the news is that the CSI Medical Index has shown a slight decline recently, reflecting the overall performance of listed companies in the medical and healthcare sector in China [1] - The CSI Medical Index closed at 6285.16 points, with a trading volume of 13.955 billion yuan, down 0.04% [1] - Over the past month, the CSI Medical Index has decreased by 8.83%, while it has seen a slight increase of 0.12% over the last three months, and a year-to-date decline of 4.13% [1] Group 2 - The CSI Medical Index includes companies involved in medical devices, medical services, and medical information technology, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the CSI Medical Index are WuXi AppTec (10.39%), Mindray Medical (9.5%), Aier Eye Hospital (8.04%), United Imaging (7.08%), Aimeike (3.67%), Huatai Medical (3.62%), Kanglong Chemical (3.16%), TigerMed (3.15%), Yuyue Medical (2.82%), and New Industry (2.74%) [1] - The market share of the CSI Medical Index is 57.96% from the Shenzhen Stock Exchange and 42.04% from the Shanghai Stock Exchange [1] - The industry composition of the CSI Medical Index shows that 97.45% is in the healthcare sector, 2.28% in information technology, and 0.27% in consumer goods [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December [2] - Weight factors are adjusted in accordance with the sample adjustments, which are fixed until the next scheduled adjustment unless a special situation arises [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to the calculation and maintenance guidelines [2]

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) closed at 2534.82 points, with a trading volume of 4.515 billion yuan, reflecting a slight increase of 0.12% [1] - Over the past month, the CS Internet Medical Index has decreased by 5.58%, while it has increased by 14.02% over the past three months and by 7.06% year-to-date [1] - The index includes representative companies that provide hardware, software, or services for medical informationization and intelligence, with a base date of June 29, 2012, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the CS Internet Medical Index are: Yifeng Pharmacy (6.75%), Daclin (6.71%), Laobaixing (6.14%), Wandong Medical (5.6%), Yixintang (5.58%), Jiuzhoutong (5.43%), Haier Biomedical (5.37%), Lepu Medical (5.32%), Yuyue Medical (5.18%), and Aier Eye Hospital (5.14%) [1] - The market share of the CS Internet Medical Index holdings is divided between Shenzhen Stock Exchange (50.91%) and Shanghai Stock Exchange (49.09%) [1] - In terms of industry composition, the holdings of the CS Internet Medical Index consist of 70.63% in pharmaceuticals and healthcare, 25.60% in information technology, and 3.77% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to calculation and maintenance guidelines [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]

金融界2025年4月22日消息，工银前沿医疗股票A(001717) 最新净值2.9210元，增长1.67%。该基金近1个 月收益率7.75%，同类排名38|1014；近3个月收益率12.82%，同类排名84|1007；今年来收益率11.02%， 同类排名80|1001。 工银前沿医疗股票A股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、药明康德（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 公开资料显示，工银前沿医疗股票A基金成立于2016年2月3日，截至2025年3月31日，工银前沿医疗股 票A规模90.81亿元，基金经理为赵蓓。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;201 ...

从指数持仓来看，中证全指医疗行业指数十大权重分别为：迈瑞医疗（14.15%）、爱尔眼科 （8.89%）、联影医疗（7.82%）、爱美客（4.05%）、惠泰医疗（4.0%）、鱼跃医疗（3.12%）、上海 医药（3.09%）、新产业（3.03%）、益丰药房（2.65%）、美年健康（2.5%）。 金融界4月22日消息，A股三大指数收盘涨跌不一，中证全指医疗行业指数 (医疗行业，932131)报537.08 点。 数据统计显示，中证全指医疗行业指数近一个月下跌5.24%，近三个月下跌0.28%，年至今下跌5.24%。 据了解，中证全指行业优选指数系列从中证全指行业中选取符合一定流动性与市值筛选条件的上市公司 作为指数样本，以反映各个行业内较具代表性与可投资性的上市公司证券的整体表现。该指数以2021年 12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证全指指数调整样本时，中证全指行业指数 ...

Core Insights - The 91st China International Medical Equipment (Spring) Expo (CMEF) was held from April 8 to 11, showcasing the latest achievements in the global medical device sector and promoting high-quality development across the entire industry chain [1] Strategic Collaborations - JD Health signed a strategic cooperation agreement with Yuyue Medical to jointly develop the Anaitang 5th generation dynamic blood glucose meter, aiming to create a comprehensive diabetes management platform that integrates AI-assisted interventions and home healthcare services, potentially covering over 5 million diabetic households [3] - A partnership with Omron Health was established to enhance AIoT blood pressure management, focusing on new product launches, health data interoperability, and innovative applications of AI technology in health management [3] - JD Health and ResMed are collaborating to reshape respiratory health services, aiming to provide a full-cycle solution from hardware sales to comprehensive health management services [4] Product Launches and Market Growth - JD Health partnered with Inco Medical to launch the Syntex™ synthetic latex gloves, utilizing a rapid delivery network to ensure swift product availability, with projected revenue growth of 200% in 2024 [4] - A collaboration with ZhenDe Medical focuses on customized products like varicose vein stockings and surgical masks, enhancing the internet+ healthcare ecosystem [5] - The company aims to redefine chronic wound care with a 24-hour response system, targeting over 500,000 chronic wound patients by 2025 [6] Industry Trends and Future Outlook - The medical device industry in China is experiencing rapid growth driven by policy incentives and consumer demand, with JD Health emerging as a preferred platform for global medical device companies [6] - JD Health's collaboration with Sanofi resulted in the successful launch of the second-generation dynamic blood glucose meter, achieving sales of over 10,000 units [6] - The company plans to continue promoting high-end products and innovative solutions in the medical device sector, aiming to break away from homogeneous competition and foster sustainable development [8]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, but it has experienced declines over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 1.17% to 13,221.28 points with a trading volume of 10.971 billion [1]. - Over the past month, the index has decreased by 9.68%, by 0.46% over the last three months, and by 4.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.26%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.36%) [1]. - The index's holdings are primarily from the Shenzhen Stock Exchange (60.12%) and the Shanghai Stock Exchange (39.88%) [1]. Group 3: Fund Tracking - Public funds tracking the healthcare index include several funds such as Southern CSI Healthcare Equipment and Services Link A, Tianhong CSI Healthcare Equipment and Services ETF, and others [2].

简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 来源：金融界 工银前沿医疗股票A股票持仓前十占比合计50.04%，分别为：恒瑞医药（9.52%）、科伦药业 （5.65%）、东阿阿胶（5.03%）、华润三九（4.81%）、华东医药（4.73%）、百济神州-U（4.40%）、 信立泰（4.38%）、昆药集团（4.04%）、鱼跃医疗（3.85%）、药明康德（3.63%）。 公开资料显示，工银前沿医疗股票A基金成立于2016年2月3日， ...

据了解，中证医疗科技指数选取30只业务涉及体外诊断、治疗设备、高值耗材、移动医疗等高端医疗器 械，以及医疗服务科技、医疗信息化等领域的上市公司证券作为指数样本，以反映医疗科技主题的整体 表现。该指数以2014年12月31日为基日，以1000.0点为基点。 从指数持仓来看，中证医疗科技指数十大权重分别为：联影医疗（10.28%）、药明康德（10.28%）、 迈瑞医疗（9.35%）、爱美客（5.22%）、惠泰医疗（4.96%）、万泰生物（4.92%）、康龙化成 （4.54%）、泰格医药（4.45%）、鱼跃医疗（3.98%）、新产业（3.9%）。 从中证医疗科技指数持仓的市场板块来看，深圳证券交易所占比52.57%、上海证券交易所占比 47.43%。 从中证医疗科技指数持仓样本的行业来看，医疗占比64.69%、医药占比30.23%、计算机占比3.29%、家 庭与个人用品占比1.79%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对 ...